A Double-Bund Crossover Comparison of Naproxen and Placebo in Rheumatoid Arthritis

Abstract

In a multi-center study, designed as a double-blind crossover, naproxen in a dose of 250 mg twice daily was compared with placebo. Each treatment period lasted two weeks. Fifty-eight patients with classical or definite active rheumatoid arthritis completed the trial. Efficacy of naproxen was demonstrated in all critical parameters measured. Preference for the drug was expressed by 40 of 58 patients. Side-effects occurred in four patients during the placebo period and in five patients during the naproxen period, in two of which side-effects seemed to be drug related. No important changes in the laboratory values were seen. It is concluded from the results of the present study that naproxen has a clearly demonstrated analgetic effect in rheumatoid arthritis. Naproxen can be regarded as a safe and well tolerated drug in the treatment of rheumatoid arthritis.